Lake Street raised the firm’s price target on Immunome (IMNM) to $32 from $22 and keeps a Buy rating on the shares after the RINGSIDE trial reached high levels of statistical significance on its key efficacy endpoints. These data “appear to be a win on all fronts and are likely to propel varegacestat to the class leader shortly after launch,” the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome price target raised to $40 from $18 at Evercore ISI
- Immunome price target raised to $35 from $25 at Guggenheim
- 3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
- Immunome offers to sell $400M in common stock
- Immunome’s Promising Outlook: Buy Rating Affirmed on Varegacestat’s Phase 3 Success and Strong Management